Hoth Therapeutics’ (HOTH) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Hoth Therapeutics (NASDAQ:HOTH) in a report released on Monday morning,Benzinga reports. The brokerage currently has a $5.00 price objective on the stock.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $4.00 price objective on shares of Hoth Therapeutics in a report on Thursday, January 23rd.

Hoth Therapeutics Stock Down 1.8 %

NASDAQ HOTH opened at $1.11 on Monday. The company has a market cap of $7.66 million, a PE ratio of -0.84 and a beta of 0.84. Hoth Therapeutics has a 52 week low of $0.58 and a 52 week high of $3.80. The firm’s 50-day simple moving average is $1.24 and its two-hundred day simple moving average is $0.99.

Institutional Investors Weigh In On Hoth Therapeutics

A hedge fund recently bought a new stake in Hoth Therapeutics stock. Virtu Financial LLC purchased a new stake in shares of Hoth Therapeutics, Inc. (NASDAQ:HOTH) during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 32,636 shares of the company’s stock, valued at approximately $29,000. Virtu Financial LLC owned 0.47% of Hoth Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 7.08% of the company’s stock.

About Hoth Therapeutics

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.